Jazz Pharmaceuticals (JAZZ) Tops Q4 EPS by 6c

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 EPS of $2.71, $0.06 better than the analyst estimate of $2.65. Revenue for the quarter came in at $396.62 million versus the consensus estimate of $398.3 million.

GUIDANCE:

Jazz Pharmaceuticals sees FY2017 EPS of $10.70-$11.30, versus the consensus of $11.33. Jazz Pharmaceuticals sees FY2017 revenue of $1.617-1.692 billion, versus the consensus of $1.68 billion.

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.

You May Also Be Interested In

• Gogoro Inc (GGR) Reports Q2 Loss of $0.24, Offers FY26 Revenue Guidance
• flyExclusive names Brian P. Reid as chief commercial officer
• Bernstein SocGen on StandardAero Inc (SARO): ' Solid revenues, but short-term margin issues'